Calamos Advisors LLC lowered its stake in Staar Surgical Co. (NASDAQ:STAA) by 29.5% during the second quarter, Holdings Channel reports. The institutional investor owned 41,100 shares of the company’s stock after selling 17,200 shares during the period. Calamos Advisors LLC’s holdings in Staar Surgical were worth $226,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of STAA. Menta Capital LLC increased its stake in shares of Staar Surgical by 26.9% in the first quarter. Menta Capital LLC now owns 75,840 shares of the company’s stock valued at $560,000 after buying an additional 16,096 shares in the last quarter. Shine Investment Advisory Services Inc. increased its stake in Staar Surgical by 24.9% in the second quarter. Shine Investment Advisory Services Inc. now owns 112,400 shares of the company’s stock worth $619,000 after buying an additional 22,400 shares during the period. Kennedy Capital Management Inc. acquired a new stake in Staar Surgical during the first quarter worth approximately $1,104,000. Renaissance Technologies LLC increased its stake in Staar Surgical by 959.2% in the first quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $1,111,000 after buying an additional 136,200 shares during the period. Finally, Geode Capital Management LLC increased its stake in Staar Surgical by 1.6% in the first quarter. Geode Capital Management LLC now owns 193,933 shares of the company’s stock worth $1,433,000 after buying an additional 3,015 shares during the period. 74.19% of the stock is owned by hedge funds and other institutional investors.
Shares of Staar Surgical Co. (NASDAQ:STAA) traded up 0.21% on Friday, hitting $9.38. The stock had a trading volume of 62,358 shares. Staar Surgical Co. has a 12-month low of $4.98 and a 12-month high of $9.78. The company’s 50-day moving average price is $9.11 and its 200 day moving average price is $7.32. The firm’s market cap is $379.24 million.
Staar Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.05) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.05). Staar Surgical had a negative return on equity of 7.12% and a negative net margin of 16.00%. The business earned $21 million during the quarter, compared to the consensus estimate of $19.88 million. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, equities research analysts forecast that Staar Surgical Co. will post ($0.30) earnings per share for the current fiscal year.
STAA has been the subject of a number of recent analyst reports. Zacks Investment Research raised Staar Surgical from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 13th. William Blair reissued a “market perform” rating on shares of Staar Surgical in a report on Thursday, August 4th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $7.50.
About Staar Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery.
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Staar Surgical Co. (NASDAQ:STAA).
Receive News & Ratings for Staar Surgical Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Staar Surgical Co. and related companies with MarketBeat.com's FREE daily email newsletter.